Big Pharma just rewrote the rulebook in the obesity-treatment race. Pfizer has won the bidding for Metsera after a showdown with Novo Nordisk.
Dan Koh and Emaad Akhtar unpack how this US$10 billion move signals a pivot into GLP-1 drugs, why Novo walked away and what it all means for investors tracking the next trillion-dollar health-tech frontier.

Bigger Pic: Why is property still our go-to wealth strategy?
07:19

Breakfast Bites: Watch it when you sail... the average cruiser gains 5kg a week!
06:12

Mind Your Business: Why these founders chose to franchise BingXue in Singapore
14:46